Enliven Therapeutics ELVN Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -27%+5.1pp | -32%— | —— | —— | |
| Liquidity | |||||
| Current ratio | 28.7×+8.7× | 20×+9.7× | 10.3×+2.3× | 8×-4.9× | |
| Leverage | |||||
| Debt-to-equity | 0×— | —— | 0×— | —— | |
| Per Share | |||||
| Book value per share | $8.11+23.2% | $6.58-4.9% | $6.92+128% | -$24.59-1,142% | |
| Valuation | |||||
| Market capitalization | $913.95M-16.9% | $1.1B+93.1% | $569.21M+429% | $107.51M+81.8% | |
| Price / book | 2×-1.6× | 3.5×+1.2× | 2.3×— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Enliven Therapeutics's ratios come from?
- Every ratio is computed from Enliven Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.